Services
A collaborative partner across the development journey
We support small-molecule programmes with bioavailability challenges from first feasibility through clinical supply. Engage us for a single screen, an enabling formulation, or an integrated programme that carries your compound from low oral exposure to a clinic-ready drug product.
Engagements can start at any stage. Bars indicate where each service sits on the path from feasibility to clinical supply; programmes are scoped to conserve API and time.
From low exposure to clinic-ready
Our integrated bioavailability programme brings assessment, screening, development, and GMP supply under one team and one timeline. We start by pinpointing the cause of low oral exposure, screen enabling technologies in parallel, and confirm the lead with biorelevant and in vivo data.
The output is a manufacturable drug product with a demonstrably improved exposure profile and a coherent CMC and regulatory narrative — the package a programme needs to progress with confidence into first-in-human studies.
Discuss your programmeHow we engage
Flexible by design
Feasibility study
A fixed-scope screen to answer one question: can an enabling formulation meaningfully improve this molecule's exposure? Fast, candid, and material-sparing.
Development programme
End-to-end formulation development with defined stage-gates, from lead selection to a scalable, stable, clinic-ready process.
Advisory & rescue
Independent assessment of a stalled programme, second-opinion formulation strategy, and targeted troubleshooting for exposure or stability problems.
Scope a programme with us
Tell us where your molecule is today and we'll propose the most material-efficient route to a confident clinical decision.